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ABSTRACT
Background: Breastfeeding increases metabolic demands on the
mother, and excessive postnatal weight loss increases maternal mor-
tality.
Objective: We evaluated the efficacy of a lipid-based nutrient sup-
plement (LNS) for prevention of excess weight loss in breastfeed-
ing, HIV-infected women.
Design: The BAN (Breastfeeding, Antiretrovirals, and Nutrition)
Study was a randomized controlled trial in Lilongwe, Malawi. At
delivery, HIV-infected mothers and their infants were randomly
assigned according to a 2-arm (with and without LNS) by 3-arm
(maternal triple-antiretroviral prophylaxis, infant-nevirapine pro-
phylaxis, or neither) factorial design. The 28-wk LNS intervention
provided daily energy (700 kcal), protein (20 g), and micronutrients
(except for vitamin A) to meet lactation needs. Women were coun-
seled to breastfeed exclusively for 24 wk and to wean by 28 wk.
Weight change (0–28 wk) was tested in an intent-to-treat analysis by
using 2-factor ANOVA and with longitudinal mixed-effects models.
Results: At delivery, the LNS (n = 1184) and control (n = 1185)
groups had similar mean weights and BMIs. Women receiving the
LNS had less 0–28-wk weight loss (21.97 compared with 22.56
kg, P = 0.003). This difference remained significant after adjust-
ment for maternal antiretroviral drug therapy and baseline BMI.
Women receiving antiretroviral drugs had more weight loss than
did those not receiving antiretroviral drugs (22.93 compared with
21.90 kg, P , 0.001). The benefit of the LNS for reducing weight
loss was observed both in those receiving antiretroviral drugs
(22.56 compared with 23.32 kg, P = 0.019) and in those not re-
ceiving antiretroviral drugs (21.63 compared with 22.16 kg, P =
0.034).
Conclusions: The LNS reduced weight loss among HIV-infected,
breastfeeding women, both in those taking maternal antiretroviral
prophylaxis to prevent postnatal HIV transmission and in those not
receiving antiretroviral prophylaxis. Provision of an LNS may benefit
HIV-infected, breastfeeding women in resource-limited settings. This
trial was registered at clinicaltrials.gov as NCT00164762. Am J
Clin Nutr 2012;95:759–65.
INTRODUCTION
The promotion of breastfeeding is central to maternal and child
health advocacy. Breastfeeding enhances maternal and child
health through increased child spacing and optimal infant nu-
trition and protection against common childhood diseases (1–3).
For the HIV-infected mother, however, breast-milk substitutes are
recommended when feasible to prevent mother-to-child trans-
mission. In resource-limited settings, replacement feeding is
often not a feasible option. In settings in which national or
subnational authorities have decided to promote and support
breastfeeding and antiretroviral interventions (even when anti-
retroviral drugs are not immediately available), the WHO rec-
ommends that mothers known to be HIV infected and whose
infants are HIV uninfected or are of unknown HIV status should
exclusively breastfeed their infants for the first 6 mo of life and
introduce appropriate complementary foods thereafter while
continuing breastfeeding through 12 mo of life (4). Breastfeeding
should then stop only once a nutritionally adequate and safe diet
without breast milk can be provided. If infants are known to be
HIV infected, mothers are strongly encouraged to exclusively
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breastfeed for the first 6 mo of life and continue breastfeeding up
to 2 y of age or beyond (4).
Breastfeeding increases the mother’s energy and nutrient
needs, and if diet during lactation is insufficient to meet the
nutritional needs of the mother and infant, breastfeeding mothers
may become nutritionally depleted (1, 5). In resource-limited
countries, nutritional depletion from breastfeeding may be ex-
acerbated by food shortages and high HIV infection rates, be-
cause HIV increases energy and nutrient needs (6). In a study in
Zambia, .10% weight loss among HIV-infected women during
lactation significantly increased subsequent mortality (7). Sim-
ilarly, in a randomized trial in HIV-infected women in Kenya,
breastfeeding mothers lost more weight and had higher rates of
mortality than did mothers randomly assigned to formula feed
(8). However, the higher mortality rate among the HIV-infected
Kenyan cohort who breastfed for a median of 17 mo was not
observed in an HIV-infected South African cohort who breastfed
for a median of 6 mo (9).
HIV-infected women in resource-limited settings may benefit
from a nutritional supplement during the breastfeeding period.
The Breastfeeding, Antiretroviral, and Nutrition (BAN) Study
was a randomized controlled trial designed to evaluate 3
objectives: 1) the effectiveness of maternal or infant anti-
retroviral drugs in preventing postnatal HIV transmission (10);
2) the effectiveness of a nutritional supplement for prevention of
maternal depletion among breastfeeding, HIV-infected women;
and 3) the feasibility of exclusive breastfeeding followed by
rapid weaning from 24 to 28 wk. The current article addresses
the second study objective.
SUBJECTS AND METHODS
The BAN Study (www.TheBANStudy.org) recruited HIV-
infected, pregnant women at 4 antenatal clinics in Lilongwe,
Malawi, from 2004 to 2009, and the screening outcomes have
been reported (10, 11). Briefly, consenting, HIV-1–infected
women (n = 3572) were screened against the following prenatal
eligibility criteria: 30 wk gestation, intention to breastfeed,
age 14 y, no serious coexisting infection, CD4+ lymphocyte
count of 250 cells/lL (200 cells/lL before 24 July 2006),
hemoglobin 7 g/dL, and alanine aminotransferase ,2.5 times
the upper limit of normal (Figure 1). Of the 463 (13%) in-
eligible women, 289 (62%) had a CD4 count below the cutoff
(10). All ineligible women were referred to a public HIV care
facility. Eligible women who delivered at a participating site
(n = 2791), along with their infants, received single-dose ne-
virapine peripartum plus twice-daily zidovudine and lamivudine
for 7 d postpartum. After delivery, 2382 mother-infant pairs met
the following postnatal eligibility criteria: presentation at the
study site within 36 h of delivery, infant birth weight 2000 g,
and no severe congenital malformations or other conditions in-
compatible with infant survival. The predominant reasons for
postnatal exclusion (n = 409) were delayed presentation to the
study site (46%) and low birth weight (20%). Thirteen women
declined further participation, and 2369 mothers completed in-
formed consent and were randomly assigned to treatment.
Mother-infant pairs were randomly assigned by using a per-
muted-block method to one of six 28-wk treatment conditions
according to a 2-arm nutritional by 3-arm antiretroviral in-
tervention factorial design and followed through 48 wk post-
partum. The 3-arm intervention required a larger sample size, and
the method used to calculate sample size has been reported (11).
A data manager generated the random allocation sequence, study
nurses screened and enrolled the women, and study pharmacists
assigned participants to interventions via sequentially numbered
envelopes. Antiretroviral drugs and lipid-based nutrient sup-
plements (LNS) were distributed by the study pharmacists at
scheduled visits occurring at 0, 1, 2, 4, 6, 8, 12, 18, 21, 24, and 28
wk postpartum.
All mother-infant pairs were randomly assigned to 1 of 2
nutritional intervention arms. Half of thewomen received an LNS
of ready-to-use food, which when taken twice-daily supplied the
estimated added energy (700 kcal), and protein (20 g) require-
ments for lactation and provided the full recommended daily
allowance of micronutrients except for vitamin A (Table 1).
Vitamin A was excluded from the LNS because of a reported
association with increased postnatal HIV transmission (12). The
LNS was manufactured by Nutriset in France (www.nutriset.fr)
from peanut paste, vegetable oil, dry skimmed milk, dry whey,
dextrin-maltose, sugar, and a mineral and vitamin complex.
Nutrient content was tested regularly by chemical analysis. The
LNS package label, in the local Chichewa language, indicated
its use for the breastfeeding mothers. To buffer seasonal food
shortages and to prevent potential sharing of the maternal LNS,
all participants—regardless of treatment assignment—received
a 2-kg/wk family maize supplement that provided ~200 kcal/
person daily for a family of 5 (13). Adherence to the LNS was
measured at 6 visits by standardized questions asked by trained
staff about the number of missed LNS packets.
FIGURE 1. Flow of HIV-infected participants through each stage of the
BAN Study. 1Prenatal and postnatal eligibility criteria are described in
Subjects and Methods. 2aThe 1184 women randomly assigned to receive
the LNS were also randomly assigned to 1 of 3 antiretroviral interventions
for prevention of postnatal HIV transmission: 424 to the maternal
antiretroviral arm, 426 to the infant nevirapine arm, and 334 to the control
arm; 2bthe 1185 women in the LNS control arm were also randomly assigned
to 1 of the 3 antiretroviral arms: 425 to the maternal antiretroviral arm, 426
to the infant nevirapine arm, and 334 to the control arm. BAN,
Breastfeeding, Antiretroviral, and Nutrition; LNS, lipid-based nutrient
supplement.
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Mother-infant pairs were randomly assigned to 1 of 3 anti-
retroviral intervention arms with drugs given to the infant,
mother, or neither. The infant nevirapine regimen consisted of an
age-adjusted daily dose of 10–30 mg nevirapine. The maternal
antiretroviral regimen included zidovudine and lamivudine plus
either nevirapine (until January 2005), nelfinavir (from January
2005 to February 2006), or lopinavir and ritonavir (Kaletra;
Abbott) (from February 2006 until study completion). Most
women who were randomly assigned to the maternal anti-
retroviral arm received the Kaletra-containing regimen (n = 664).
On 26 March 2008, the National Institute of Allergy and In-
fectious Diseases Vaccine and Prevention Data and Safety
Monitoring Board recommended stopping enrollment to the
antiretroviral control arm after 668 of the planned 806 mother-
infant pairs received their treatment assignment. The BAN
Study halted random assignment to the control arm and offered
mothers on that arm and who were <21 wk postpartum the
choice to initiate the maternal or infant antiretroviral in-
tervention or to remain on the control arm (11).
At all study visits, maternal weight was measured by using
a regularly calibrated electronic scale, and height was measured
by using a wall-mounted stadiometer. Some women with 5%
weight loss between visits occurring 4 wk postpartum or
a BMI (in kg/m2) ,17 (n = 25) were offered the LNS if not
already receiving it (n = 13 and 12 in the maternal antiretroviral
and no-maternal-antiretroviral arms, respectively).
With the use of a standardized protocol derived from theWHO
Breastfeeding Counseling Training Manual (14), all mothers
were individually counseled to breastfeed exclusively for 24 wk
then to rapidly wean to breastfeeding cessation by 28 wk (15). In
addition, BAN Study nurses conducted weekly breastfeeding
support groups. To minimize concern for infant malnutrition
during breastfeeding cessation, the study provided a locally
produced ready-to-use therapeutic food for the infants (16).
Breastfeeding practices and timing of breastfeeding cessa-
tion were captured by trained staff by using standardized
questionnaires.
Ethics
The BAN protocol and study forms were approved by the
Malawi National Health Science Research Commission, the
institutional review boards at the University of North Carolina at
Chapel Hill, and the CDC (clinicaltrials.gov; NCT00164762).
The trial was monitored for safety and efficacy by the National
Institute of Allergy and Infectious Diseases Vaccine and Pre-
vention Data and Safety Monitoring Board.
Statistical analyses
The dependent variable for the primary analysis was maternal
weight loss between delivery and 28 wk postpartum. Complete
data to calculate this variable were available for 848 and 853
mothers receiving the LNS intervention and control arms who
had both a delivery weight and a 28-wk weight. For the analysis,
we focused on 4 groups defined by maternal antiretroviral and
LNS assignment. Mothers whose infants were assigned to receive
antiretroviral drugs were included with the no-maternal-anti-
retroviral arms, resulting in groups defined as LNS with (n = 424)
and without (n = 760) antiretroviral drugs and no LNS with (n =
425) and without (n = 760) antiretroviral drugs (Figure 1).
Differences between mean weights of mothers randomly as-
signed to the LNS intervention arm and mothers randomly as-
signed to the LNS control arm, overall, and within groups
stratified by maternal antiretroviral assignment were evaluated
by using 2-factor ANOVA procedures with a = 0.05.
Womenwith at least oneweight measurement at any time point
were included in a secondary repeated-measures longitudinal
analysis (1182 and 1181 mothers in the LNS intervention and
control arms, respectively). Linear mixed-effects models with an
autoregressive covariance structure were used to evaluate weight
from 0 to 28 wk, with adjustment for initial BMI at delivery to
account for the expected dependence of weight change on starting
weight. Potential interactions of the LNS with study visit, the
maternal antiretroviral intervention with study visit, and of the
LNS with the maternal antiretroviral intervention were evaluated.
Predicted values were calculated by adding the appropriate fixed-
effects variables for study visit, LNS, and maternal antiretroviral
intervention with mean initial BMI and used to create predicted
weight-change curves for each intervention. All data analysis
used SAS 9.2 software (SAS Institute Inc).
RESULTS
Women in the LNS arm (n = 1184) were no different from
those in the control arm (n = 1185) with respect to socio-
demographic characteristics and anthropometric and laboratory
measures collected at random assignment (Table 2). The ma-
jority (72%) of women were exposed to the famine season
(August to March) within 4 wk before giving birth, and yet their
mean baseline BMI was 23.6. Of the women on the maternal
antiretroviral arm, 77.4% took Kaletra, and there was no dif-
ference in drug regimens between the LNS intervention (77.4%)
and control (77.4%) arms. A similar analysis restricted to the
TABLE 1
Composition (per 70-g sachet) of the twice-daily maternal nutritional












Vitamin B-1, thiamine (mg) 0.8
Vitamin B-2, riboflavin (mg) 0.9
Vitamin B-3, niacin (mg) 10
Vitamin B-6, pyridoxine (mg) 1.1
Vitamin B-12, cyanocobalamine (lg) 1.3
Vitamin C, ascorbic acid (mg) 50
Vitamin E, a-tocopherol (mg) 6
Folic acid (lg) 150
Iodine (lg) 200
1 The supplement was manufactured by Nutriset in France (www.nutriset.
fr) from peanut paste, vegetable fat, dry skimmed milk, dry whey, dextrin-
maltose, sugar, and a mineral and vitamin complex. BAN, Breastfeeding,
Antiretroviral, and Nutrition.
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848 and 853 mothers receiving the LNS intervention and control
arms who had both a delivery weight and a 28-wk weight also
found no significant differences with respect to baseline char-
acteristics. A comparison of women included in the primary
analysis with those in the secondary analysis (those with at least
one weight measurement) showed that the former had a higher
mean age (26.1 compared with 24.9 y; P , 0.001) and parity
(3.2 compared with 2.8; P , 0.001).
Adherence to the LNS was high, and the supplement was well
tolerated. Overall, women reported taking the prescribed amount
of supplement on the day before the visit an average of 92.4% of
the time (over adherence assessments collected at 6 visits between
0 and 28 wk). Women reported taking none of the supplement on
the prior day <5% of the time. There was no significant difference
in adherence to the LNS across the 3 antiretroviral intervention
arms (P = 0.421). The self-reported frequency of exclusive
breastfeeding was high in both the LNS intervention and control
groups (97% and 96%, respectively, at 21 wk).
Between delivery and 28-wk postpartum, women in the LNS
control arm (n = 853) lost an average of 2.56 kg and those in the
LNS intervention arm (n = 848) lost an average of 1.97 kg (P =
0.003) (Figure 2, Table 3). These numbers remained relatively
unchanged in sensitivity analyses that excluded the 25 women
who were given LNS because of weight loss (22.54 and 21.97
kg, P = 0.004). The benefit of the LNS for reduced weight loss
was observed in the first 12 wk postpartum: between 0 and 2 wk,
21.27 compared with21.50 kg (P = 0.018); between 2 and 4 wk,
20.06 compared with 20.31 kg (P , 0.001); and between 4 and
12 wk, 20.08 compared with 20.35 kg (P = 0.007). Between 12
and 28 wk, there was no significant difference in weight loss be-
tween the LNS intervention and control arms (P = 0.939) (Table 3).
Women in the antiretroviral arm lost more weight from 0 to 28
wk than did those not provided with antiretroviral drugs (22.93
compared with 21.90 kg, respectively; P , 0.001). Within both
the maternal antiretroviral arm and the no-maternal-antiretroviral
arms, women receiving LNS lost less weight from 0 to 28 wk than
did those not receiving the LNS (22.56 compared with23.32 kg
in the maternal antiretroviral arms, P = 0.019; 21.63 compared
with22.16 kg in the no-maternal-antiretroviral arms, P = 0.034).
In a linear mixed-effects model with adjustment for BMI at
delivery, significant interactions were observed between study
TABLE 2
Mean baseline characteristics of the BAN Study participants in the primary
analysis of the effects of an LNS provided to HIV-infected Malawian
women during lactation1
LNS (n = 1184) No LNS (n = 1185)
Age (y) 25.8 6 5.02 25.7 6 5.0
Postprimary education (%) 36.4 32.9
Parity (n) 3.1 6 1.6 3.0 6 1.5
Cesarean delivery (%) 5.1 6.0
Married (%) 93.6 91.9
Electricity in home (%) 20.0 18.8
Exposed to famine season3 (%) 72.2 72.1
Anthropometric measurements
Height (cm) 156.8 6 5.5 156.9 6 5.6
Weight (kg) 57.7 6 8.4 58.4 6 8.6
BMI (kg/m2) 23.4 6 3.0 23.7 6 3.0
Laboratory measures
Hemoglobin (g/dL) 11.7 6 1.6 11.8 6 1.7
Albumin (g/L) 2.6 6 0.3 2.6 6 0.5
CD4 count (cells/lL) 482.0 6 205.2 472.9 6 188.5
Antiretroviral intervention arm (%)




No-antiretroviral-drugs arm (%) 28.2 28.2
1 There were no significant (P , 0.05) differences between the LNS and
the no-LNS arms. BAN, Breastfeeding, Antiretroviral, and Nutrition; LNS,
lipid-based nutrient supplement.
2 Mean 6 SD (all such values).
3 Women were defined as exposed to the famine season (August–
March) if it occurred within 4 wk before delivery.
4 The BAN Study changed the maternal antiretroviral therapy regimen
twice during the course of the study for reasons of availability, safety, and
potency. The majority (77.4%) of women in the maternal antiretroviral ther-
apy arm used lopinavir/ritonavir (Kaletra; Abbott) for both the nutrient-rich
supplement arm (77.4%) and the family maize–only arm (77.4%).
FIGURE 2. Mean (6SE) cumulative maternal weight loss by random assignment to the LNS and weeks since delivery among BAN Study participants.
The mean (6SE) weight loss was calculated from delivery cumulatively at each visit and includes data for all women with at least one weight measurement
(n = 1182 in the LNS intervention arm, n = 1181 in the control arm). BAN, Breastfeeding, Antiretroviral, and Nutrition; LNS, lipid-based nutrient supplement.
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visit and the antiretroviral intervention (P, 0.001), and between
study visit and the LNS intervention (P , 0.001). The in-
teraction between the LNS and the antiretroviral intervention
was not significant (P = 0.16), and neither was the 3-way in-
teraction between the LNS, antiretroviral intervention, and study
visit (P = 0.81). On the basis of predicted curves from the
model, weight loss was the lowest among mothers who received
the LNS without the maternal antiretroviral intervention and
greatest among women who received the maternal antiretroviral
intervention without the LNS (Figure 3).
DISCUSSION
HIV-infected, breastfeeding women in the BAN Study who
received a LNS in addition to a family maize provision had
significantly less weight loss from delivery to 28 wk postpartum
compared with those who received the family maize alone. The
benefit of the LNS for prevention of weight loss was greatest in
the earlier postpartum period. The significant reduction in weight
loss associated with the LNS was observed in women randomly
assigned to the maternal antiretroviral intervention for prevention
of postnatal HIV transmission to the infant and in those randomly
assigned to not receive antiretroviral drugs.Whereas the observed
benefit of the LNS was greater in those women who were ran-
domly assigned to receive antiretroviral drugs (a 0.76 kg dif-
ference between the LNS and control groups in women receiving
antiretroviral drugs, and a 0.53 kg difference between the LNS
and control groups in those not receiving antiretroviral drugs),
this was not supported by a significant interaction between the
LNS and antiretroviral drugs in a longitudinal mixed-effects
model. Although the LNS was significantly associated with less
weight loss, the difference in average weight loss between the
LNS intervention and control arms was small. Furthermore, the
average percentage weight loss from 0 to 28 wk in the LNS
intervention (3.4%) and control (4.4%) arms was not in excess of
what is expected during this postpartum period for physiologic
reasons, including changes in body water, uterine size, and
mobilization of fat stores to support milk production (17). This
finding is somewhat surprising given the high exposure to the
famine season and food insecurity during the study period, and
the generally poor quality of diets of Malawian women. The
dietary intake of 577 potential BAN participants during preg-
nancy showed that their mean daily energy intake was low (1378
kcal), and the most frequent dietary pattern was characterized by
a low intake of fruits, vegetables, and meats (18). World Food
Programme distributions occurred during the study period, but
neither a variable indicating receipt of food from the World Food
Programme nor a variable for study year was significant in the
multivariable model. Alternatively, the BAN Study provision of
TABLE 3
Weight at delivery and postpartum weight change in BAN Study
participants in the primary analysis of the effects of an LNS provided to
HIV-infected Malawian women during lactation1
LNS No LNS
Outcome n Mean 6 SD n Mean 6 SD P value
Weight (kg)
Delivery 57.90 6 8.51 58.51 6 8.63
28 wk 55.94 6 9.24 55.95 6 8.48
Difference
0–28 wk 848 21.97 6 4.17 853 22.56 6 4.09 0.003
0–2 wk 997 21.27 6 1.99 970 21.50 6 2.37 0.018
2–4 wk 892 20.06 6 1.19 882 20.31 6 1.17 ,0.001
4–12 wk 872 20.08 6 2.10 873 20.35 6 2.03 0.007
12–28 wk 821 20.44 6 2.59 828 20.43 6 2.50 0.939
1 Differences were adjusted for maternal antiretroviral group; P values
represent results from a 2-factor ANOVA. BAN, Breastfeeding, Antiretro-
viral, and Nutrition; LNS, lipid-based nutrient supplement.
FIGURE 3. Predicted maternal weight change over weeks since delivery by random assignment to the LNS and maternal antiretroviral interventions in the
BAN Study. Predicted curves from a mixed-effects model containing study visit (P, 0.001), nutritional supplement (P = 0.009), maternal antiretroviral drugs
(P = 0.025), BMI at delivery (P , 0.001), and 2-way interactions between study visit and nutritional supplement (P , 0.001), between study visit and
maternal antiretroviral drugs (P , 0.001), and between nutritional supplement and maternal antiretroviral drugs (P = 0.16). The 3-way interaction between
study visit, maternal antiretroviral drugs, and nutritional supplement was not significant (P = 0.81) and was not included in the final model. Data from all
women with at least one weight measurement were included (LNS, maternal antiretroviral drugs: n = 423; LNS, no maternal antiretroviral drugs: n = 759; no
LNS, maternal antiretroviral drugs: n = 424; and no LNS, no maternal antiretroviral drugs: n = 757). BAN, Breastfeeding, Antiretroviral, and Nutrition; LNS,
lipid-based nutrient supplement.
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a family maize supplement to all participants may have partially
met the energy needs of breastfeeding and reduced the potential
effect of the LNS intervention.
For ethical reasons, women with 5% weight loss between
visits and who were not already in the LNS intervention arm
were given LNS as a therapeutic intervention. However, the
number of women who received LNS because of weight loss
was small (n = 25); a sensitivity analysis with these women
removed did not alter the significance of study results, so this
practice is not likely to have biased our results.
Prior literature provides conflicting reports on whether
breastfeeding leads to nutritional depletion and even mortality
among HIV-infected women (7–9, 19–21). A trial conducted in
Kenya reported that breastfeeding mothers lost more weight than
did womenwhowere randomly assigned to formula feed, and that
each kilogram of weight loss per month was associated with
a 3.4-times higher risk of dying in the first 24 mo postpartum (8).
More recent studies that looked at prolonged breastfeeding
reported no increased mortality or faster HIV disease progression
among HIV-infected, breastfeeding women (19–21). These
studies speculated that the Kenyan results may be a chance
finding due in part to differences across the study arms in viral
load at randomization and the duration of follow-up for accrual of
deaths. In contrast, the Zvitambo study in Zambia found that
.10% weight loss among HIV-infected, lactating women in-
creased subsequent mortality .7-fold (7).
The lower postpartum weight loss with the LNS observed in
the BAN Study may not be generalizable to all HIV-infected
women in resource-limited settings. On average, women enrolled
in the BAN Study were likely healthier than HIV-infected
mothers in Malawi due to the study inclusion criteria and high-
quality health care provided in the postpartum period. As such,
the benefit of the LNS among breastfeeding women with poorer
nutritional status or more advanced HIV disease is unknown.
Random assignment to the LNS and antiretroviral intervention
arms occurred within 36 h of delivery. To conduct an appropriate
intent-to-treat analysis, the interval for weight change included
the early postpartum period, when normal physiologic changes
are expected. The inclusion of the early postpartum period and
the lack of complete information on prepregnancy weight and
weight gain during pregnancy may complicate the interpretation
of postpartum weight loss. But, in the absence of differences
between treatment arms in maternal weight at delivery, it is
unlikely that results would differ even if we could account for the
prenatal changes. We adjusted for BMI at delivery to reduce the
error variance in the estimation of weight change.
As is the case with all food-based nutrition supplementation
trials, blinding was not possible. Lack of blinding is very unlikely
to have biased weight measurements. However, it is possible that
women who knew they were getting an energy- and nutrient-rich
supplement adjusted their home intake or their intake of the
study-provided family maize supplement so that the difference in
total energy intake between the LNS and no-LNS groups was not
as high as intended. Unfortunately, the absence of dietary intake
data on the full sample of BAN participants does not allow us to
determine whether the LNS was substituted for a portion of usual
intake. We do not know whether the LNS resulted in a net in-
crease in energy intake in the LNS intervention group compared
with the no-LNS group. Nevertheless, the comparison of weight
loss across the 2 LNS intervention arms should remain valid. We
have no reason to believe that the loss to follow-up observed in
the BAN Study differentially affected the study outcomes, be-
cause participants with a 28-wk visit remained equally balanced
and representative of the total population who were randomly
assigned according to sociodemographic, anthropometric, and
laboratory values at baseline.
In conclusion, HIV-infected women randomly assigned to
receive an LNS and family maize provision during 28 wk of
breastfeeding had less weight loss than did women receiving only
the family maize. The benefit of the LNS for prevention of weight
loss was observed in the earlier postpartum period and among
both women randomly assigned to the maternal antiretroviral
intervention and those randomly assigned to not receive the ma-
ternal antiretroviral intervention. Although the difference in weight
loss between the nutritional arms over the breastfeeding period
reached statistical significance, the actual difference was small and
may be of limited clinical significance. However, we cannot rule
out the potential value of maternal LNS for HIV-infected
breastfeeding women in the early postpartum period, particularly
for those who are initiating triple-drug antiretroviral regimens,
because the effect noted in this study was likely mitigated by the
provision of a family maize supplement to all participants.
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